Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study

[1]  D. Angiolillo,et al.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease , 2016, Nature Reviews Cardiology.

[2]  D. Angiolillo,et al.  Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.

[3]  G. Veress,et al.  Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. , 2014, Journal of the American College of Cardiology.

[4]  D. Angiolillo,et al.  Platelet Function Testing in Contemporary Clinical and Interventional Practice , 2014, Current Treatment Options in Cardiovascular Medicine.

[5]  R. Abbate,et al.  Switching from clopidogrel to prasugrel in patients having coronary stent implantation , 2014, Journal of Thrombosis and Thrombolysis.

[6]  H. Suryapranata,et al.  Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience , 2014, Journal of Thrombosis and Thrombolysis.

[7]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[8]  Mandeep Singh,et al.  An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.

[9]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[10]  I. Xanthopoulou,et al.  Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular interventions.

[11]  D. Prabhakaran,et al.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. , 2012, JAMA.

[12]  H. White,et al.  Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. , 2012, JACC. Cardiovascular interventions.

[13]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[14]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[15]  S. Werns.  Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial , 2012 .

[16]  M. Price,et al.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.

[17]  I. Xanthopoulou,et al.  Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. , 2011, American heart journal.

[18]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[19]  T. Costigan,et al.  Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. , 2010, Journal of the American College of Cardiology.

[20]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[21]  D. Aradi,et al.  Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. , 2010, American heart journal.

[22]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[23]  Sunil V. Rao,et al.  Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years , 2010, Circulation. Cardiovascular interventions.

[24]  G. Montalescot,et al.  Prasugrel compared with high-dose clopidogrel in acute coronary syndrome , 2009, Thrombosis and Haemostasis.

[25]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[26]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[27]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[28]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[29]  P. Gurbel,et al.  The difference between clopidogrel responsiveness and posttreatment platelet reactivity. , 2005, Thrombosis research.

[30]  H. White,et al.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.

[31]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.